Immunoneutralization of c-Fos using intrathecal antibody electroporation attenuates chronic constrictive injury-induced hyperalgesia and regulates preprodynorphin expression in rats.
BACKGROUND
In vivo electroporation has been successfully used for the introduction of DNA, RNA, oligonucleotides, and proteins into cells for experimental and therapeutic purposes. The authors evaluated the efficacy of electroporation-mediated c-Fos antibody therapy for neuropathic pain in vitro and in vivo.


METHODS
First, the authors studied the inhibitory effects of intrathecal c-Fos antibody electroporation on the activating protein (AP-1) promoter activity in cultured spinal neuronal cells transfected with p-AP-Luc plasmid and activated with 100 microm glutamate. The inhibitory effect of c-Fos antibody electroporation in the regulation of AP-1 promoter activity was assessed according to the relative luciferase activity. Second, rats with chronic constrictive injury underwent electroporation treatment for neuropathic pain using c-Fos antibody. Thermal nociceptive thresholds were measured before chronic constrictive injury and then on even-numbered days, up to and including day 14, to assess and compare the therapeutic effects of intrathecal electroporation. The time course was assessed by Western blot analysis and by immunohistochemical analysis. Pronociceptive gene expression was measured by assessing prodynorphin mRNA and dynorphin peptides on days 2 and 10 after intrathecal c-Fos electroporation.


RESULTS
Cotransfection of c-Fos antibody significantly decreased glutamate-induced AP-1 activity. Intrathecal electrotransfer of c-Fos antibody attenuated spinal dynorphin levels, as manifested by significantly elevated pain thresholds in the chronic constrictive injury-affected limbs.


CONCLUSIONS
This study shows that transfer of antibody into rat spinal cords by intrathecal electroporation is a useful method to study the function of endogenous factors of spinal-related disorders.
D000818:Animals; D000906:Antibodies / Q000235:genetics / Q000627:therapeutic use*; D002478:Cells, Cultured; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004399:Dynorphins / Q000096:biosynthesis* / Q000235:genetics; D018274:Electroporation / Q000379:methods*; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D016762:Genes, fos / Q000235:genetics / Q000502:physiology*; D006930:Hyperalgesia / Q000188:drug therapy* / Q000378:metabolism; D007278:Injections, Spinal; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D011498:Protein Precursors / Q000096:biosynthesis* / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D020426:Sciatic Neuropathy / Q000188:drug therapy / Q000378:metabolism; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism
D000906:Antibodies; D011498:Protein Precursors; C036448:pre-prodynorphin; D004399:Dynorphins